Pfizer Free Cash Flow 2010-2023 | PFE
Pfizer annual/quarterly free cash flow history and growth rate from 2010 to 2023. Free cash flow can be defined as a measure of financial performance calculated as operating cash flow minus capital expenditures.
- Pfizer free cash flow for the quarter ending December 31, 2023 was 4,793.00, a year-over-year.
- Pfizer free cash flow for the twelve months ending December 31, 2023 was , a year-over-year.
- Pfizer annual free cash flow for 2023 was $4.793B, a 81.59% decline from 2022.
- Pfizer annual free cash flow for 2022 was $26.031B, a 12.85% decline from 2021.
- Pfizer annual free cash flow for 2021 was $29.869B, a 145.29% increase from 2020.
| Pfizer Annual Free Cash Flow |
| 2023 |
4,793.00 |
| 2022 |
26,031.00 |
| 2021 |
29,869.00 |
| 2020 |
12,177.00 |
| 2019 |
10,542.00 |
| 2018 |
13,843.00 |
| 2017 |
14,846.00 |
| 2016 |
14,369.00 |
| 2015 |
13,291.00 |
| 2014 |
15,885.00 |
| 2013 |
16,478.00 |
| 2012 |
15,419.00 |
| 2011 |
18,580.00 |
| 2010 |
9,941.00 |
| 2009 |
15,382.00 |
| Pfizer Quarterly Free Cash Flow |
| 2023-12-31 |
4,793.00 |
| 2023-09-30 |
597.00 |
| 2023-06-30 |
-2,049.00 |
| 2023-03-31 |
73.00 |
| 2022-12-31 |
26,031.00 |
| 2022-09-30 |
18,450.00 |
| 2022-06-30 |
13,317.00 |
| 2022-03-31 |
5,898.00 |
| 2021-12-31 |
29,869.00 |
| 2021-09-30 |
24,957.00 |
| 2021-06-30 |
14,746.00 |
| 2021-03-31 |
3,984.00 |
| 2020-12-31 |
12,177.00 |
| 2020-09-30 |
7,365.00 |
| 2020-06-30 |
5,782.00 |
| 2020-03-31 |
2,684.00 |
| 2019-12-31 |
10,542.00 |
| 2019-09-30 |
7,315.00 |
| 2019-06-30 |
3,370.00 |
| 2019-03-31 |
1,238.00 |
| 2018-12-31 |
13,843.00 |
| 2018-09-30 |
9,732.00 |
| 2018-06-30 |
5,020.00 |
| 2018-03-31 |
1,597.00 |
| 2017-12-31 |
14,846.00 |
| 2017-09-30 |
8,457.00 |
| 2017-06-30 |
4,018.00 |
| 2017-03-31 |
1,226.00 |
| 2016-12-31 |
14,369.00 |
| 2016-09-30 |
9,017.00 |
| 2016-06-30 |
4,712.00 |
| 2016-03-31 |
1,507.00 |
| 2015-12-31 |
13,291.00 |
| 2015-09-30 |
9,004.00 |
| 2015-06-30 |
4,273.00 |
| 2015-03-31 |
441.00 |
| 2014-12-31 |
15,885.00 |
| 2014-09-30 |
10,640.00 |
| 2014-06-30 |
6,452.00 |
| 2014-03-31 |
2,643.00 |
| 2013-12-31 |
16,478.00 |
| 2013-09-30 |
11,171.00 |
| 2013-06-30 |
5,549.00 |
| 2013-03-31 |
2,101.00 |
| 2012-12-31 |
15,419.00 |
| 2012-09-30 |
10,965.00 |
| 2012-06-30 |
6,247.00 |
| 2012-03-31 |
2,520.00 |
| 2011-12-31 |
18,580.00 |
| 2011-09-30 |
13,917.00 |
| 2011-06-30 |
9,932.00 |
| 2011-03-31 |
4,392.00 |
| 2010-12-31 |
9,941.00 |
| 2010-09-30 |
4,230.00 |
| 2010-06-30 |
-2,165.00 |
| 2010-03-31 |
-6,665.00 |
| 2009-12-31 |
15,382.00 |
| 2009-09-30 |
10,979.00 |
| 2009-06-30 |
7,139.00 |
| 2009-03-31 |
2,894.00 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$157.249B |
$58.496B |
|
Pfizer Inc. is a research-based, global biopharmaceutical company. The company boasts a sustainable pipeline with multiple late-stage programs that can drive growth. Pfizer markets a wide range of drugs and vaccines. Its business comprises six business units - Oncology, Inflammation & Immunology, Rare Disease, Hospital, Vaccines and Internal Medicine. Pfizer spinned-off its Upjohn unit, its off-patent branded and generic established medicines business, and combined it with generic drugmaker Mylan to create a new generic pharmaceutical company called Viatris. The Consumer Healthcare (CHC) segment, an over-the-counter (OTC) medicines business, was merged with Glaxo's unit to form a new joint venture.?The Consumer Healthcare joint venture with Glaxo and the merger of Upjohn unit with Mylan has made Pfizer a smaller company with a diversified portfolio of innovative drugs and vaccines.
|
